Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Experimental Therapeutics

Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis

Gary A. Piazza, Alanna L. Kulchak Rahm, Mary Krutzsch, Gerhard Sperl, Nancy Shipp Paranka, Paul H. Gross, Klaus Brendel, Randall W. Burt, David S. Alberts, Rifat Pamukcu and Dennis J. Ahnen
Gary A. Piazza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alanna L. Kulchak Rahm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Krutzsch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Sperl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Shipp Paranka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul H. Gross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Brendel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall W. Burt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Alberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rifat Pamukcu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis J. Ahnen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published July 1995
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The nonsteroidal anti-inflammatory drug sulindac is known to inhibit chemical carcinogenesis in rodent models and cause regression of adenomas in patients with adenomatous polyposis coli. Sulindac is a prodrug that is metabolized to a pharmacologically active sulfide derivative that potently inhibits prostaglandin synthesis. Recent studies, however, have shown that a sulfone derivative of sulindac, which essentially lacks prostaglandin synthesis inhibitory activity, also inhibits chemical carcinogenesis, suggesting that reduction of prostaglandin levels is not necessary for the antineoplastic activity of this class of drugs. Both sulindac sulfide and the sulfone inhibit the growth of cultured tumor cells, although the cellular mechanism(s) responsible for the antineoplastic activity of sulindac derivatives is unknown. In this study, we investigated the effects of sulindac sulfide and sulfone on the proliferation, differentiation, and apoptosis of HT-29 human colon carcinoma cells. Sulindac sulfide and sulfone significantly reduced cell number in both preconfluent and confluent cultures of HT-29 cells with the sulfide showing approximately 4-fold greater potency. In addition to HT-29 cells, both drugs inhibited the growth of a variety of tumor cell lines derived from other tissues, as well as normal epithelial cells and fibroblasts. Neither sulindac sulfide nor sulfone inhibited cell proliferation under conditions where the drugs were growth inhibitory. Only under specific conditions involving mitogenic stimulation did sulindac sulfide and sulfone cause cell cycle arrest. Neither sulindac sulfide nor the sulfone induced differentiation of HT-29 cells, but both drugs strongly induced apoptosis. The apoptotic response to sulindac sulfide and sulfone was both time- and dose-dependent and involved a mechanism independent of their inhibitory effect on cell cycle progression. These data suggest that apoptosis is responsible for the cell growth inhibitory activity of sulindac sulfide and sulfone and represents a potential mechanism for the antineoplastic activity of these drugs.

Footnotes

  • ↵1 Supported by Cell Pathways Inc., and Veterans Administration Merit Review Grant 1312 and the Flow Cytometry and Immunology Shared Resources of the University of Colorado Cancer Center. D. J. A. is the recipient of a Department of Veterans Affairs Clinical Investigator Award.

  • ↵2 To whom requests for reprints should be addressed, at Cell Pathways, Inc., 1300 South Potomac Street, Suite 110, Denver, CO 80012-4526.

  • Received March 9, 1995.
  • Accepted May 16, 1995.
  • ©1995 American Association for Cancer Research.
PreviousNext
Back to top
July 1995
Volume 55, Issue 14
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis
Gary A. Piazza, Alanna L. Kulchak Rahm, Mary Krutzsch, Gerhard Sperl, Nancy Shipp Paranka, Paul H. Gross, Klaus Brendel, Randall W. Burt, David S. Alberts, Rifat Pamukcu and Dennis J. Ahnen
Cancer Res July 15 1995 (55) (14) 3110-3116;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis
Gary A. Piazza, Alanna L. Kulchak Rahm, Mary Krutzsch, Gerhard Sperl, Nancy Shipp Paranka, Paul H. Gross, Klaus Brendel, Randall W. Burt, David S. Alberts, Rifat Pamukcu and Dennis J. Ahnen
Cancer Res July 15 1995 (55) (14) 3110-3116;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental Therapeutics

  • The Biological and Biochemical Effects of CP-654577, a Selective erbB2 Kinase Inhibitor, on Human Breast Cancer Cells
  • Novel Mechanisms of Apoptosis Induced by Histone Deacetylase Inhibitors
  • Phosphatidylinositol 3′-Kinase Is Required for Growth of Mast Cells Expressing the Kit Catalytic Domain Mutant
Show more Experimental Therapeutics

Articles

  • BRCA1, BRCA2, and Rad51 Operate in a Common DNA Damage Response Pathway
  • Introduction of H. Robert Horvitz
  • Membership of Selection Committees
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement